Treatment Approaches in Pediatric Relapsing Autoimmune Encephalitis
Open Access
- 21 March 2024
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 26 (5) , 139-149
Abstract
Purpose of review: Autoimmune encephalitis (AE) is increasingly recognized as a treatable cause of encephalitis in children. While prior observational studies demonstrate improved motor outcomes with early immunotherapy, less is known about long-term management and treatment for relapsing disease. In this review, we present current treatment approaches to pediatric AE, in particular relapse risk and treatment for relapsing AE in children. Recent findings: A recent meta-analysis of anti-NMDAR encephalitis demonstrated that disease onset in adolescence was associated with an increased odds of relapse whereas treatment with rituximab and IVIG for 6 months or longer were associated with a non-relapsing course. However, no specific pediatric sub-analyses were reported. A single-center study on adult and pediatric AE showed that rituximab use was associated with a reduction in time to relapse and recurring relapses although the data for the pediatric cohort did not achieve statistical significance. Summary: The use of second-line immunotherapy during the initial attack may reduce the risk for relapsing disease in pediatric AE. Larger studies are needed to investigate relapse risk and treatment in both anti-NMDAR and non-NMDAR encephalitis in children.Keywords
This publication has 53 references indexed in Scilit:
- Autoimmune encephalitis and CSF anti-AMPA GluR3 antibodies in childhood: a case report and literature reviewNeurological Sciences, 2022
- Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody EncephalitisJAMA Neurology, 2021
- Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young AdultsJAMA Network Open, 2021
- Correction to: Refractory anti‑NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature reviewJournal of Neurology, 2021
- Autoimmune encephalitis epidemiology and a comparison to infectious encephalitisAnnals of Neurology, 2018
- Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patientsAnnals of Neurology, 2017
- Autoimmune Glial Fibrillary Acidic Protein AstrocytopathyJAMA Neurology, 2016
- Bortezomib Treatment for Patients With Anti-N-Methyl-d-Aspartate Receptor EncephalitisJAMA Neurology, 2016
- Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort StudyNeurotherapeutics, 2016
- Anti–N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis in children and adolescentsAnnals of Neurology, 2009